Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 487

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 2
Chunk 487
---
 10.29
     
    June 5, 2024

    10.30†
     
    Amendment No. 1 to Strategic Collaboration Agreement, by and between the Registrant and GlaxoSmithKline LLC, dated May 20, 2024.
     
    S-1/A
     
    333-279558
     
    10.30
     
    June 5, 2024

    10.31#
     
    Securities Purchase Agreement, by and among the Registrant, REALM IDx, Inc. and Konica Minolta, Inc., dated November 4, 2024
     
    8-K
     
    001-42130
     
    10.1
     
    November 5, 2024

    10.32#
     
    Third Amendment to Credit Agreement and First Amendment to Guarantee and Collateral Agreement, dated as of February 3, 2025, by and among the Company, certain subsidiaries of the Company party thereto, the lenders party thereto, Ares Capital Corporation, as administrative agent and ACF Finco I LP, as revolving agent.
     
    8-K
     
    001-42130
     
    10.1
     
    February 3, 2025

    10.33
     
    Start-Up Agreement by and between the Registrant and Pathos AI, Inc., dated August 1, 2024
     
    10-Q
     
    333-279558
     
    10.11
     
    November 5, 2024

    10.34*
     
    Eighth Amendment to Agreement of Lease, dated as of June 18, 2024, by and between the Registrant and EQC 600 West Chicago Property LLC.

    19.1*
     
    Insider Trading Policy.

    21.1
     
    List of subsidiaries of the Registrant
     
    S-1/A
     
    333-279558
     
    21.1
     
    June 5, 2024

    23.1*
     
    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.

    24.1*
     
    Power of Attorney (included on signature pages).

    31.1*
     
    Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 

    31.2*
     
    Certification of